2012 Indiana Code
TITLE 35. CRIMINAL LAW AND PROCEDURE
ARTICLE 41. SUBSTANTIVE CRIMINAL PROVISIONS
CHAPTER 1. JURISDICTION AND DEFINITIONS

IC 35-41
ARTICLE 41. SUBSTANTIVE CRIMINAL PROVISIONS

IC 35-41-1
Chapter 1. Jurisdiction and Definitions

IC 35-41-1-0.1
Application of certain amendments to chapter
Sec. 0.1. The addition of section 5.5 of this chapter by P.L.80-2008 applies only to persons convicted after June 30, 2008.
As added by P.L.220-2011, SEC.590. Amended by P.L.63-2012, SEC.44.

IC 35-41-1-1
Jurisdiction
Sec. 1. (a) As used in this section, "Indiana" includes:
(1) the area within the boundaries of the state of Indiana, as set forth in Article 14, Section 1 of the Constitution of the State of Indiana;
(2) the portion of the Ohio River on which Indiana possesses concurrent jurisdiction with the state of Kentucky under Article 14, Section 2 of the Constitution of the State of Indiana; and
(3) the portion of the Wabash River on which Indiana possesses concurrent jurisdiction with the state of Illinois under Article 14, Section 2 of the Constitution of the State of Indiana.
(b) A person may be convicted under Indiana law of an offense if:
(1) either the conduct that is an element of the offense, the result that is an element, or both, occur in Indiana;
(2) conduct occurring outside Indiana is sufficient under Indiana law to constitute an attempt to commit an offense in Indiana;
(3) conduct occurring outside Indiana is sufficient under Indiana law to constitute a conspiracy to commit an offense in Indiana, and an overt act in furtherance of the conspiracy occurs in Indiana;
(4) conduct occurring in Indiana establishes complicity in the commission of, or an attempt or conspiracy to commit, an offense in another jurisdiction that also is an offense under Indiana law;
(5) the offense consists of the omission to perform a duty imposed by Indiana law with respect to domicile, residence, or a relationship to a person, thing, or transaction in Indiana;
(6) conduct that is an element of the offense or the result of conduct that is an element of the offense, or both, involve the use of the Internet or another computer network (as defined in IC 35-43-2-3) and access to the Internet or other computer network occurs in Indiana; or
(7) conduct: (A) involves the use of:
(i) the Internet or another computer network (as defined in IC 35-43-2-3); or
(ii) another form of electronic communication;
(B) occurs outside Indiana and the victim of the offense resides in Indiana at the time of the offense; and
(C) is sufficient under Indiana law to constitute an offense in Indiana.
(c) When the offense is homicide, either the death of the victim or bodily impact causing death constitutes a result under subsection (b)(1). If the body of a homicide victim is found in Indiana, it is presumed that the result occurred in Indiana.
(d) If the offense is identity deception or synthetic identity deception, the lack of the victim's consent constitutes conduct that is an element of the offense under subsection (b)(1). If a victim of identity deception or synthetic identity deception resides in Indiana when a person knowingly or intentionally obtains, possesses, transfers, or uses the victim's identifying information, it is presumed that the conduct that is the lack of the victim's consent occurred in Indiana.
As added by Acts 1976, P.L.148, SEC.1. Amended by Acts 1977, P.L.340, SEC.1; P.L.295-1995, SEC.1; P.L.115-2005, SEC.3; P.L.125-2006, SEC.8; P.L.137-2009, SEC.12.

IC 35-41-1-2
Repealed
(Repealed by P.L.311-1983, SEC.49.)

IC 35-41-1-3
Repealed
(Repealed by P.L.114-2012, SEC.80.)

IC 35-41-1-3.1
Repealed
(Repealed by P.L.1-2010, SEC.156.)

IC 35-41-1-3.2
Repealed
(Repealed by P.L.114-2012, SEC.81.)

IC 35-41-1-3.3
Repealed
(Repealed by P.L.1-2010, SEC.156.)

IC 35-41-1-3.4
Repealed
(Repealed by P.L.114-2012, SEC.82.)

IC 35-41-1-3.5 Version a
"Analog" Note: This version of section effective until 7-1-2012. See also following repeal of this section, effective 7-1-2012.
Sec. 3.5. "Analog", for purposes of section 26.3 of this chapter, means a new or novel chemical entity, independent of synthetic route or natural origin, having substantially the same:
(1) carbon backbone structure; and
(2) pharmacological mechanism of action;
as a compound specifically defined as a synthetic drug in section 26.3 of this chapter.
As added by P.L.78-2012, SEC.10.

IC 35-41-1-3.5 Version b
Repealed
(Repealed by P.L.114-2012, SEC.83.)
Note: This repeal of section effective 7-1-2012. See also preceding version of this section, effective until 7-1-2012.

IC 35-41-1-4
Repealed
(Repealed by P.L.114-2012, SEC.84.)

IC 35-41-1-4.3
Repealed
(Repealed by P.L.114-2012, SEC.85.)

IC 35-41-1-4.4
Repealed
(Repealed by P.L.114-2012, SEC.86.)

IC 35-41-1-4.5
Repealed
(Repealed by P.L.9-1990, SEC.17.)

IC 35-41-1-4.6
Repealed
(Repealed by P.L.114-2012, SEC.87.)

IC 35-41-1-4.7
Repealed
(Repealed by P.L.114-2012, SEC.88.)

IC 35-41-1-5
Repealed
(Repealed by P.L.114-2012, SEC.89.)

IC 35-41-1-5.5
Repealed
(Repealed by P.L.114-2012, SEC.90.)

IC 35-41-1-6 Repealed
(Repealed by P.L.114-2012, SEC.91.)

IC 35-41-1-6.3
Repealed
(Repealed by P.L.114-2012, SEC.92.)

IC 35-41-1-6.5
Repealed
(Repealed by P.L.114-2012, SEC.93.)

IC 35-41-1-6.6
Repealed
(Repealed by P.L.114-2012, SEC.94.)

IC 35-41-1-7
Repealed
(Repealed by P.L.114-2012, SEC.95.)

IC 35-41-1-8
Repealed
(Repealed by P.L.114-2012, SEC.96.)

IC 35-41-1-8.5
Repealed
(Repealed by P.L.114-2012, SEC.97.)

IC 35-41-1-9
Repealed
(Repealed by P.L.114-2012, SEC.98.)

IC 35-41-1-10
Repealed
(Repealed by P.L.114-2012, SEC.99.)

IC 35-41-1-10.3
Repealed
(Repealed by P.L.114-2012, SEC.100.)

IC 35-41-1-10.5
Repealed
(Repealed by P.L.114-2012, SEC.101.)

IC 35-41-1-10.6
Repealed
(Repealed by P.L.114-2012, SEC.102.)

IC 35-41-1-10.7
Repealed
(Repealed by P.L.1-2003, SEC.106.)
IC 35-41-1-10.8
Repealed
(Repealed by P.L.114-2012, SEC.103.)

IC 35-41-1-11
Repealed
(Repealed by P.L.114-2012, SEC.104.)

IC 35-41-1-12
Repealed
(Repealed by P.L.114-2012, SEC.105.)

IC 35-41-1-12.3
Repealed
(Repealed by P.L.114-2012, SEC.106.)

IC 35-41-1-13
Repealed
(Repealed by P.L.114-2012, SEC.107.)

IC 35-41-1-14
Repealed
(Repealed by P.L.114-2012, SEC.108.)

IC 35-41-1-15
Repealed
(Repealed by P.L.114-2012, SEC.109.)

IC 35-41-1-16
Repealed
(Repealed by P.L.114-2012, SEC.110.)

IC 35-41-1-16.5
Repealed
(Repealed by P.L.114-2012, SEC.111.)

IC 35-41-1-17
Repealed
(Repealed by P.L.114-2012, SEC.112.)

IC 35-41-1-18
Repealed
(Repealed by P.L.114-2012, SEC.113.)

IC 35-41-1-18.3
Repealed
(Repealed by P.L.114-2012, SEC.114.)

IC 35-41-1-18.5 Repealed
(Repealed by P.L.114-2012, SEC.115.)

IC 35-41-1-19
Repealed
(Repealed by P.L.114-2012, SEC.116.)

IC 35-41-1-19.3
Repealed
(Repealed by P.L.114-2012, SEC.117.)

IC 35-41-1-19.4
Repealed
(Repealed by P.L.114-2012, SEC.118.)

IC 35-41-1-20
Repealed
(Repealed by P.L.114-2012, SEC.119.)

IC 35-41-1-21
Repealed
(Repealed by P.L.114-2012, SEC.120.)

IC 35-41-1-22
Repealed
(Repealed by P.L.114-2012, SEC.121.)

IC 35-41-1-23
Repealed
(Repealed by P.L.114-2012, SEC.122.)

IC 35-41-1-23.7
Repealed
(Repealed by P.L.114-2012, SEC.123.)

IC 35-41-1-24
Repealed
(Repealed by P.L.114-2012, SEC.124.)

IC 35-41-1-24.2
Repealed
(Repealed by P.L.114-2012, SEC.125.)

IC 35-41-1-24.3
Repealed
(Repealed by P.L.114-2012, SEC.126.)

IC 35-41-1-24.7
Repealed
(Repealed by P.L.114-2012, SEC.127.)
IC 35-41-1-24.8
Repealed
(Repealed by P.L.114-2012, SEC.128.)

IC 35-41-1-25
Repealed
(Repealed by P.L.114-2012, SEC.129.)

IC 35-41-1-26
Repealed
(Repealed by P.L.114-2012, SEC.130.)

IC 35-41-1-26.3 Version a
"Synthetic cannabinoid"
Note: This version of section amended by P.L.6-2012, SEC.224, effective until 7-1-2012. See also following version of this section amended by P.L.78-2012, SEC.11, effective until 7-1-2012, and following repeal of this section, effective 7-1-2012.
Sec. 26.3. "Synthetic cannabinoid" means a substance containing one (1) or more of the following chemical compounds:
(1) JWH-015 ((2-Methyl-1-propyl-1H- indol-3-yl)-1-naphthalenylmethanone).
(2) JWH-018 (1-pentyl-3-(1-naphthoyl)indole).
(3) JWH-019 (1-hexyl-3-(naphthalen-1-oyl)indole).
(4) JWH-073 (naphthalen-1-yl-(1-butylindol-3-yl)methanone).
(5) JWH-081 (4-methoxynaphthalen- 1-yl- (1-pentylindol- 3-yl)methanone).
(6) JWH-122 (1-Pentyl-3-(4-methyl-1-naphthoyl)indole).
(7) JWH-200 ((1-(2-morpholin-4-ylethyl)indol-3-yl)- naphthalen-1-ylmethanone).
(8) JWH-250 (1-pentyl-3-(2-methoxyphenylacetyl)indole).
(9) JWH-251 (1-pentyl-3-(2-methylphenylacetyl)indole).
(10) JWH-398 (1-pentyl-3-(4-chloro-1-naphthoyl)indole).
(11) HU-210 ((6aR,10aR)- 9-(Hydroxymethyl)- 6,6-dimethyl- 3-(2-methyloctan-2-yl)- 6a,7,10,10a-tetrahydrobenzo [c]chromen- 1-ol).
(12) HU-211 ((6aS,10aS)-9-(Hydroxymethyl)- 6,6-dimethyl- 3-(2-methyloctan-2-yl)- 6a,7,10,10a-tetrahydrobenzo [c]chromen-1-ol).
(13) HU-308 ([(1R,2R,5R)-2-[2,6-dimethoxy-4-
(2-methyloctan- 2-yl)phenyl]-
7,7-dimethyl-4-bicyclo[3.1.1]hept-3-enyl] methanol).
(14) HU-331 (3-hydroxy-2- [(1R,6R)-3-methyl-6- (1-methylethenyl)-2 -cyclohexen-1-yl]-5 -pentyl-2,5-cyclohexadiene-1,4-dione).
(15) CP 55,940 (2-[(1R,2R,5R)-5-hydroxy-2-(3-hydroxypropyl) cyclohexyl]- 5- (2-methyloctan-2-yl)phenol).
(16) CP 47,497 (2-[(1R,3S)-3-hydroxycyclohexyl]- 5- (2-methyloctan-2-yl)phenol) and its homologues. (17) WIN 55212-2
((R)-(+)-[2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl) pyrrolo [1,2,3-de)- 1,4- benzoxazin- 6-yl]-1-napthalenylmethanone).
(18) RCS-4 ((4-methoxyphenyl) (1-pentyl-1H-indol-3-yl)methanone).
(19) RCS-8 (1-(1-(2-cyclohexylethyl)-1H- indol-3-yl)-2-(2-methoxyphenyl)ethanone).
(20) 4-Methylmethcathinone. Other name: mephedrone.
(21) 3,4-Methylenedioxymethcathinone. Other name: methylone.
(22) Fluoromethcathinone.
(23) 4-Methoxymethcathinone. Other name: methedrone.
(24) 4-Ethylmethcathinone (4-EMC).
(25) Methylenedioxypyrovalerone. Other name: MDPV.
As added by P.L.138-2011, SEC.10; P.L.182-2011, SEC.10. Amended by P.L.6-2012, SEC.224.

IC 35-41-1-26.3 Version b
"Synthetic drug"
Note: This version of section amended by P.L.78-2012, SEC.11, effective until 7-1-2012. See also preceding version of this section amended by P.L.6-2012, SEC.224, effective until 7-1-2012, and following repeal of this section, effective 7-1-2012.
Sec. 26.3. "Synthetic drug" means:
(1) a substance containing one (1) or more of the following chemical compounds, including an analog of the compound:

(A) JWH-015 ((2-Methyl-1-propyl-1H- indol-3-yl)-1-naphthalenylmethanone).

(B) JWH-018 (1-pentyl-3-(1-naphthoyl)indole).
(C) JWH-019 (1-hexyl-3-(naphthalen-1-oyl)indole).

(D) JWH-073 (naphthalen-1-yl-(1-butylindol-3-yl)methanone).

(E) JWH-081 (4-methoxynaphthalen- 1-yl- (1-pentylindol- 3-yl)methanone).
(F) JWH-122 (1-Pentyl-3-(4-methyl-1-naphthoyl)indole).
(G) JWH-200 ((1-(2-morpholin-4-ylethyl)indol-3-yl)- naphthalen-1-yl-methanone).
(H) JWH-250 (1-pentyl-3-(2-methoxyphenylacetyl)indole).
(I) JWH-251 (1-pentyl-3-(2-methylphenylacetyl)indole).
(J) JWH-398 (1-pentyl-3-(4-chloro-1-naphthoyl)indole).
(K) HU-210 ((6aR,10aR)- 9-(Hydroxymethyl)- 6,6-dimethyl- 3-(2-methyloctan-2-yl)- 6a,7,10,10a-tetrahydrobenzo [c]chromen- 1-ol).
(L) HU-211 ((6aS,10aS)-9-(Hydroxymethyl)- 6,6-dimethyl- 3-(2-methyloctan-2-yl)- 6a,7,10,10a-tetrahydrobenzo [c]chromen-1-ol).
(M) HU-308 ([(1R,2R,5R)-2-[2,6-dimethoxy-4- (2-methyloctan- 2-yl)phenyl]- 7,7-dimethyl-4-bicyclo[3.1.1]hept-3-enyl] methanol). (N) HU-331 (3-hydroxy-2- [(1R,6R)-3-methyl-6- (1-methylethenyl)-2 -cyclohexen-1-yl]-5 -pentyl-2,5-cyclohexadiene-1,4-dione).

(O) CP 55,940 (2-[(1R,2R,5R)-5-hydroxy-2-(3-hydroxypropyl) cyclohexyl]- 5- (2-methyloctan-2-yl)phenol).

(P) CP 47,497 (2-[(1R,3S)-3-hydroxycyclohexyl]- 5- (2-methyloctan-2-yl)phenol) and its homologues, or
2-[(1R,3S)-3-hydroxycyclohexyl]-5-(2-methyloctan-2-yl)
phenol), where side chain n=5, and homologues where side chain n=4, 6, or 7.

(Q) WIN 55212-2 ((R)-(+)-[2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl) pyrrolo [1,2,3-de)- 1,4- benzoxazin- 6-yl]-1-napthalenylmethanone).

(R) RCS-4 ((4-methoxyphenyl) (1-pentyl-1H-indol-3-yl)methanone).

(S) RCS-8 (1-(1-(2-cyclohexylethyl)-1H- indol-3-yl)-2-(2-methoxyphenyl)ethanone).

(T) 4-Methylmethcathinone. Other name: mephedrone.
(U) 3,4-Methylenedioxymethcathinone. Other name: methylone.
(V) Fluoromethcathinone.
(W) 4-Methoxymethcathinone. Other name: methedrone.
(X) 4-Ethylmethcathinone (4-EMC).
(Y) Methylenedioxypyrovalerone. Other name: MDPV.
(Z) JWH-007, or 1-pentyl-2-methyl-3-(1-naphthoyl)indole.

(AA) JWH-098, or 1-pentyl-2-methyl-3-(4-methoxy-1-naphthoyl)indole.

(BB) JWH-164, or 1-pentyl-3-(7-methoxy-1-naphthoyl)indole.

(CC) JWH-210, or 1-pentyl-3-(4-ethyl-1-naphthoyl)indole.

(DD) JWH-201, or 1-pentyl-3-(4-methoxyphenylacetyl)indole.

(EE) JWH-203, or 1-pentyl-3-(2-chlorophenylacetyl)indole.
(FF) AM-694, or
1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole.
(GG) CP 50,556-1, or
[(6S,6aR,9R,10aR)-9-hydroxy-6-methyl-3-[(2R)-5-phenyl pentan-2-yl]oxy-5,6,6a,7,8,9,10,10a-octahydrophenanthrid
in-1-yl] acetate.
(HH) Dimethylheptylpyran, or DMHP.
(II) 4-Methyl-alpha-pyrrolidinobutiophenone, or MPBP.
(JJ) 6-APB [6-(2-aminopropyl)benzofuran].
(LL) 7-hydroxymitragynine.
(MM) .-PPP [.-pyrrolidinopropiophenone].
(NN) .-PVP (desmethylpyrovalerone).
(OO) AM-251.
(PP) AM-1241.
(QQ) AM-2201. (RR) AM-2233.
(SS) Buphedrone.
(TT) Butylone.
(UU) CP-47,497-C7.
(VV) CP-47,497-C8.
(WW) Desoxypipradol.
(XX) Ethylone.
(YY) Eutylone.
(ZZ) Flephedrone.
(AAA) JWH-011.
(BBB) JWH-020.
(CCC) JWH-022.
(DDD) JWH-030.
(EEE) JWH-182.
(FFF) JWH-302.
(GGG) MDAI [5,6-methylenedioxy-2-aminoindane].
(HHH) Mitragynine.
(III) Naphyrone.
(JJJ) Pentedrone.
(LLL) Pentylone.
(MMM) Methoxetamine
[2-(3-methoxyphenyl)-2-(ethylamino)- cyclohexanone].
(2) Any compound structurally derived from 3-(1-naphthoyl)indole or 1H-indol-3-yl-(1-naphthyl)methane by substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent.
(3) Any compound structurally derived from 3-(1-naphthoyl) pyrrole by substitution at the nitrogen atom of the pyrrole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the pyrrole ring to any extent and whether or not substituted in the naphthyl ring to any extent.
(4) Any compound structurally derived from 1-(1-naphthylmethyl)indene by substitution at the 3-position of the indene ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indene ring to any extent and whether or not substituted in the naphthyl ring to any extent.
(5) Any compound structurally derived from 3-phenylacetylindole by substitution at the nitrogen atom of the indole ring with alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted

in the phenyl ring to any extent.
(6) Any compound structurally derived from 2-(3-hydroxycyclohexyl)phenol by substitution at the 5-position of the phenolic ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or not substituted in the cyclohexyl ring to any extent.
(7) Any compound containing a 3-(benzoyl)indole structure with substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent.
(8) Any compound, except bupropion or a compound listed under a different schedule, structurally derived from 2-aminopropan-1-one by substitution at the 1-position with either phenyl, naphthyl, or thiophene ring systems, whether or not the compound is further modified:
(A) by substitution in the ring system to any extent with alkyl, alkylenedioxy, alkoxy, haloalkyl, hydroxyl, or halide substituents, whether or not further substituted in the ring system by one or more other univalent substituents;
(B) by substitution at the 3-position with an acyclic alkyl substituent;
(C) by substitution at the 2-amino nitrogen atom with alkyl, dialkyl, benzyl, or methoxybenzyl groups; or
(D) by inclusion of the 2-amino nitrogen atom in a cyclic structure.
(9) Any compound determined to be a synthetic drug by rule adopted under IC 25-26-13-4.1.
As added by P.L.138-2011, SEC.10; P.L.182-2011, SEC.10. Amended by P.L.78-2012, SEC.11.

IC 35-41-1-26.3 Version c
Repealed
(Repealed by P.L.114-2012, SEC.131.)
Note: This repeal of section effective 7-1-2012. See also preceding version of this section amended by P.L.6-2012, SEC.224, effective until 7-1-2012, and preceding version of this section amended by P.L.78-2012, SEC.11, effective until 7-1-2012.

IC 35-41-1-26.5
Repealed
(Repealed by P.L.114-2012, SEC.132.)

IC 35-41-1-26.8
Repealed
(Repealed by P.L.105-2010, SEC.18.)
IC 35-41-1-27
Repealed
(Repealed by P.L.114-2012, SEC.133.)

IC 35-41-1-28
Repealed
(Repealed by P.L.114-2012, SEC.134.)

IC 35-41-1-29
Repealed
(Repealed by P.L.114-2012, SEC.135.)

IC 35-41-1-29.4
Repealed
(Repealed by P.L.114-2012, SEC.136.)